Abstract
Backgrounds and Objectives: This investigation described clinicopathological features and outcomes of extraskeletal myxoid chondrosarcoma (EMC) patients. Methods: EMC patients were identified from the United States Sarcoma Collaborative database between 2000 and 2016. Overall survival (OS) and recurrence-free survival (RFS) were calculated, and prognostic factors were analyzed. Results: Sixty individuals with a mean age of 55 years were included, and 65.0% (n = 39) were male. 73.3% (n = 44) had a primary tumor. A total of 41.6% (n = 25) developed tumor relapse following resection. The locoregional recurrence rate was 30.0% (n = 18/60), and mean follow-up was 42.7 months. The 5-year OS was 71.0%, while the 5-year RFS was 41.4%. On multivariate analysis for all EMC, chemotherapy (hazard ratio [HR], 6.054; 95% confidence interval [CI], 1.33−27.7; p = 0.020) and radiation (HR, 5.07, 95% CI, 1.3−20.1; p = 0.021) were independently predictive of a worse RFS. Among patients with primary EMC only, the 5-year OS was 85.3%, with a 30.0% (n = 12) locoregional recurrence rate, though no significant prognostic factors were identified. Conclusions: Long-term survival with EMC is probable, however there exists a high incidence of locoregional recurrence. While chemotherapy and radiation were associated with a worse RFS, these findings were likely confounded by recurrent disease as significance was lost in the primary EMC-only subset.
Original language | English (US) |
---|---|
Pages (from-to) | 1533-1542 |
Number of pages | 10 |
Journal | Journal of Surgical Oncology |
Volume | 126 |
Issue number | 8 |
DOIs | |
State | Published - Dec 15 2022 |
Externally published | Yes |
Keywords
- extraskeletal myxoid chondrosarcoma
- outcomes
- prognosis
- soft tissue sarcoma
- survival
ASJC Scopus subject areas
- Surgery
- Oncology